Company: CMND
Filing Date: 2025-09-15
Form Type: POS AM
Source: 0001213900-25-087398
Chunk: 8

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-15
Form: POS AM
Chunk 8
---
, Israel as additional clinical sites for our ongoing Phase I/IIa clinical trial.
In addition, also in June 2025, we announced that the first patient was enrolled and dosed
in our Phase I/IIa clinical trial at Yale School of Medicine’s Department of Psychiatry.
In July 2025, we announced that we received IRB approval from TASMC for our Phase I/IIa clinical
trial , and in August 2025, we announced that we received IRB approval from Hadassah-University
Medical Center. In July 2025, we announced initiation of the TASMC clinical site.

The CM-CMND-001 clinical trial is designed to
be a multinational, multi-center, double blind, Phase I/IIa single- and multiple-dose tolerability, safety and pharmacokinetic study
in healthy volunteers and AUD subjects. Upon completion of the Phase I/IIa studies, if successful, we will be required to conduct additional
clinical trials subject to securing additional financing.

About MEAI

MEAI
is a synthetic molecule. Its mechanism of action has been studied and published in the past
in scientific papers. It was found to interact with the serotonergic receptors 5-HT1A and
5-HT2B and the adrenergic receptors α2A, α2B and α2C receptors. The interaction
with the 5HT2B receptor was determined as non-agonist activity. Studies conducted in animals
and humans have demonstrated the role of 5-HT1A receptors in alcohol-drinking behavior. Several
5-HT1A receptor agonists have been tested in animal models to demonstrate the role of this
receptor in alcohol dependence. These preclinical studies suggest that 5-HT1A receptor agonists
may play a role in reducing alcohol intake. In addition, evidence suggests that α2-adrenergic
receptor agonist signaling may play a role in mediating alcohol-drinking behavior in both
rodents and humans.

<div align='center'>1</div>

The literature shows that 5-HT1A receptors are
associated with controlling craving behaviors across the board. This indicates that MEAI may have a wide range of applications beyond
AUD and binge drinking. Until today, only pre-clinical studies have been conducted with MEAI, including in-vitro and in-vivo studies.
The studies were conducted in the United States, China, France and Israel.

MEAI
is a neuroplastogens